<DOC>
	<DOCNO>NCT00978731</DOCNO>
	<brief_summary>To determine long term safety tolerability dasatinib exposure subject previously treat CA180-002 .</brief_summary>
	<brief_title>Chronic Myelogenous Leukemia Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>This study enrol participant Philadelphia chromosome positive ( Ph+ ) chronic myelogenous leukemia ( CML ) Ph+ acute lymphoblastic leukemia ( ALL ) demonstrate hematologic resistance intolerance imatinib mesylate ( Gleevec ) experience clinical benefit ( Investigator 's opinion ) protocol CA180002 . Signed write informed consent Previous treatment dasatinib protocol CA180002 receive clinical benefit opinion investigator Completed minimum 3 month protocol CA180002 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 ( See Appendix 1 ) Prior history Ph+ chronic , accelerate , blast phase CML Ph+ ALL Women childbearing potential ( WOCBP ) unwilling unable use acceptable method avoid pregnancy entire study period 12 week study WOCBP use prohibit contraceptive method Women pregnant breastfeeding Met criterion define protocol CA180002 discontinuation therapy include : Withdrawal inform consent ( subject 's decision withdraw reason ) Any clinical adverse event , laboratory abnormality intercurrent illness , opinion investigator , indicate continued treatment dasatinib best interest subject Imprisonment compulsory detention treatment either psychiatric physical ( e.g. , infectious disease ) illness Medical History Concurrent Diseases A serious uncontrolled medical disorder active infection would impair ability patient receive protocol therapy ; Uncontrolled angina within 3 month Diagnosed suspected congenital long QT syndrome Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) Prolonged correct QT ( QTc ) interval preentry electrocardiogram ( &gt; 450 msec ) Uncontrolled hypertension Dementia alter mental status would prohibit understanding rendering informed consent ; History significant bleeding disorder unrelated CML , include : 1 . Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) 2 . Diagnosed acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) Physical Laboratory Test Findings Total bilirubin ≥ 1.5 mg/dl alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≥ 2 time institutional upper limit normal Serum creatinine ≥ 1.5 time institutional upper limit normal Prohibited Therapies and/or Medications Patients currently take drug generally accept risk cause Torsades de Pointes include : quinidine , procainamide , disopyramide amiodarone , sotalol , ibutilide , dofetilide erythromycin , clarithromycin chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine . Medications inhibit platelet function nonsteroidal antiinflammatory drug ) anticoagulant prohibit unless previous exception CA180002 grant medical monitor . Subjects take anagrelide thrombocytosis due CML eligible protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>